Latanoprost Horus Pharma (Latanoprost)

Latanoprost is a prostaglandin analog used to manage conditions characterized by elevated intraocular pressure.

• Open-angle glaucoma: reduces intraocular pressure and slows disease progression.
• Ocular hypertension: lowers eye pressure to prevent development of glaucoma.
• Pseudoexfoliative glaucoma: provides pressure reduction in this secondary form of glaucoma.

• Latanoprost binds to prostaglandin F (FP) receptors in the ciliary muscle, activating a cascade that remodels extracellular matrix and enhances uveoscleral outflow of aqueous humor. The increased drainage lowers intraocular pressure, thereby reducing stress on the optic nerve and helping to preserve visual fields in glaucomatous eyes.

Latanoprost may cause ocular and peri‑ocular reactions, most of which are mild and reversible.

Common Side Effects

• Eye redness: transient hyperemia of the conjunctiva.
• Increased eyelash growth: longer, thicker lashes.
• Iris darkening: gradual hyperpigmentation of the iris.
• Eye irritation: burning or stinging sensation.
• Blurred vision: temporary visual disturbance.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Uveitis: inflammation of the uveal tract.
• Macular edema: fluid accumulation in the central retina.
• Paradoxical rise in intraocular pressure.
• Corneal edema: swelling of the cornea.
• Ocular infection: increased risk if sterility is compromised.

Before initiating therapy, clinicians should evaluate ocular health and consider potential risk factors.

• Monitor intraocular pressure: assess response after initiation.
• Avoid use in active ocular inflammation: may exacerbate condition.
• Caution in patients with a history of herpetic eye disease: risk of reactivation.
• Review concomitant ocular medications: assess for additive effects.
• Do not wear contact lenses during treatment: may trap drug residue.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Latanoprost can interact with other ophthalmic agents, influencing efficacy or safety.

Major Interactions (Avoid)

• Concurrent use with other prostaglandin analogs: may increase ocular irritation.
• Combination with ocular anesthetics: can heighten discomfort.
• Simultaneous administration of multiple intraocular pressure‑lowering drops without supervision: risk of excessive pressure reduction.

Moderate Interactions (Monitor Closely)

• Systemic beta‑blockers: additive IOP‑lowering effect may require monitoring.
• Topical corticosteroids: may diminish Latanoprost efficacy.
• Certain contact lens solutions: could affect drug stability and absorption.